A Phase 1 interventional study of Ripretinib and Repaglinide in GIST - Gastrointestinal Stromal Tumor, sponsored by Deciphera Pharmaceuticals, LLC. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Deciphera Pharmaceuticals, LLC (part of Ono Pharmaceutical Co. Ltd) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Gastrointestinal Stromal Tumors by Ono Pharmaceutical Co. Ltd — 2 open to participants now, 5 under way, 2 of them phase 3. Gastrointestinal Stromal Tumors · Ono Pharmaceutical Co. Ltd.
Among the 10 studies in Gastrointestinal Stromal Tumors by Ono Pharmaceutical Co. Ltd, this one is one of 2 that started in 2021, is one of 3 in phase 1, and was the 5th registered.
343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.
Browse Gastrointestinal Stromal Tumors studies →2 of the 10 studies in Gastrointestinal Stromal Tumors by Ono Pharmaceutical Co. Ltd are open now, in 2 countries. Recruiting first, the newest first:
Ono Pharmaceutical Co., Ltd. · Sites in Japan
Ages 18+
Deciphera Pharmaceuticals, LLC · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 3 · Phase 3 3
First in 2015; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13 is below the median of 50 across 252 interventional studies indexed under Gastrointestinal Stromal Tumors.
Median enrollment 94 across the 9 interventional studies. Of the 3 that completed or were terminated, 1 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Deciphera Pharmaceuticals, LLC, one of the names counted as Ono Pharmaceutical Co. Ltd. Under that name alone:
Deciphera Pharmaceuticals, LLC is the lead sponsor of 24 studies on the registry; 5 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 3 (30%) have results posted.
1 of the studies in Gastrointestinal Stromal Tumors by Ono Pharmaceutical Co. Ltd that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05957367Deciphera Pharmaceuticals, LLCA Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Gastrointestinal Stromal Tumors by Ono Pharmaceutical Co. Ltd, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Substrate
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Gastrointestinal abnormalities including but not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single dose of repaglinide 0.5 mg (1 × 0.5-mg tablet) will be administered orally on Cycle 1 Day 1 and Cycle 1 Day 15. Ripretinib 150 mg QD (3 × 50-mg tablets) will be administered orally from Day 2 through Day 28 for Cycle 1 and will be administered continuously from Cycle 2 until disease progression as assessed by the Investigator, unacceptable toxicity, or withdrawal of consent.
Drug: Ripretinib · Drug: Repaglinide
Oral KIT/PDGFRA kinase inhibitor
Also known as: QINLOCK
Oral antihyperglycemic agent
Maximum Observed Plasma Concentration for Repaglinide
Measure the Cmax
Time frame: Cycle 1 Day 1 and Cycle 1 Day 15 (pre-dose and at multiple time points [up to 24 hours] post-dose). Each cycle is 28 days.
Area under the concentration-time curve (AUC) from time 0 up to time t (AUC0-t) for Repaglinide
Measure the AUC0-t
Time frame: Cycle 1 Day 1 and Cycle 1 Day 15 (pre-dose and at multiple time points [up to 24 hours] post-dose). Each cycle is 28 days.
AUC from time 0 and extrapolated to infinity (AUC0-∞)
Measure the AUC0-∞
Time frame: Cycle 1 Day 1 and Cycle 1 Day 15 (pre-dose and at multiple time points [up to 24 hours] post-dose). Each cycle is 28 days.
Incidence of Adverse Events
Adverse events \[TEAEs, SAEs\], dose reduction, dose interruption, or discontinuation, vital signs (heart rate \[beats/min\], and changes in laboratory parameters (chemistry, hematology, urinalysis, coagulation).
Time frame: Cycle 1 through study completion (~ 12 months). Each cycle is 28 days.
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2021 to primary completion in Nov 2023, 25 months.
Of 21 phase 1 interventional studies under Gastrointestinal Stromal Tumors, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 77. This study's 25 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ripretinib · Repaglinide
Gastrointestinal Stromal Tumors →
Deciphera Pharmaceuticals, LLC →